In total, 23.5% shows clinical response (1/34 had complete clinical response, 7/34 had partial response), and >50% showed no disease progression at 12 weeks (compared to expected mean PFS of 8 weeks in this population with current treatment). Responders had more CD3 cell infiltration into tumor. PDL1 expression in tumor correlated with better clinical response. Here, CD274 is linked to neoplasm.